What's the outlook for RXST's EPS in 2025?

RxSight's EPS outlook for 2025 is positive, with expected growth driven by revenue expansion.

1. Revenue Growth: RxSight anticipates full-year 2025 revenue to be in the range of $185.0 million to $197.0 million, reflecting a significant increase of approximately 32% to 41% compared to 2024. This growth is supported by the company's successful product sales and market expansion.
2. Gross Margin Stability: The company reaffirms a gross margin range of 71% to 73% for 2025, indicating a stable and healthy profit margin that should support EPS growth. Gross profit margin is a key indicator of a company's profitability and is expected to remain strong, which is a positive signal for EPS.
3. Operating Expenses: RxSight expects operating expenses to be high, ranging from $150 million to $160 million for 2025. While this suggests a significant investment in operations, it does not necessarily preclude EPS growth if revenue expansion outpaces expense increases.
4. Analyst Confidence: The consensus rating for RxSight is "Neutral" with an average analyst price target of $32.87, suggesting a moderate level of optimism among analysts for the company's future performance. This target price is significantly higher than the current price, indicating potential upside for the stock.

In conclusion, while specific EPS figures for 2025 are not available, the company's strong revenue growth prospects, stable gross margins, and analyst optimism all point to a positive outlook for EPS in 2025.